These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 17943832)

  • 1. Intermittent versus continuous androgen suppression for prostatic cancer.
    Conti PD; Atallah AN; Arruda H; Soares BG; El Dib RP; Wilt TJ
    Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD005009. PubMed ID: 17943832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
    Nair B; Wilt T; MacDonald R; Rutks I
    Cochrane Database Syst Rev; 2002; (1):CD003506. PubMed ID: 11869665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
    Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009266. PubMed ID: 24979481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
    Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
    Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for prostate cancer.
    Ilic D; Neuberger MM; Djulbegovic M; Dahm P
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer.
    Kunath F; Jensen K; Pinart M; Kahlmeyer A; Schmidt S; Price CL; Lieb V; Dahm P
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD003506. PubMed ID: 31194882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).
    Schulman C; Cornel E; Matveev V; Tammela TL; Schraml J; Bensadoun H; Warnack W; Persad R; Salagierski M; Gómez Veiga F; Baskin-Bey E; López B; Tombal B
    Eur Urol; 2016 Apr; 69(4):720-727. PubMed ID: 26520703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
    Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Degarelix for treating advanced hormone-sensitive prostate cancer.
    Zengerling F; Jakob JJ; Schmidt S; Meerpohl JJ; Blümle A; Schmucker C; Mayer B; Kunath F
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD012548. PubMed ID: 34350976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.
    Magnan S; Zarychanski R; Pilote L; Bernier L; Shemilt M; Vigneault E; Fradet V; Turgeon AF
    JAMA Oncol; 2015 Dec; 1(9):1261-9. PubMed ID: 26378418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radical prostatectomy versus deferred treatment for localised prostate cancer.
    Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent androgen suppression in the LuCaP 23.12 prostate cancer xenograft model.
    Buhler KR; Santucci RA; Royai RA; Whitney SC; Vessella RL; Lange PH; Ellis WJ
    Prostate; 2000 Apr; 43(1):63-70. PubMed ID: 10725867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hormone release and intermittent hormonal therapy in the LN CaP model of human prostate cancer].
    Gleave M; Santo N; Rennie PS; Goldenberg SL; Bruchovsky N; Sullivan LD
    Prog Urol; 1996 Jun; 6(3):375-85. PubMed ID: 8763692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer.
    Boccon-Gibod L; Albers P; Morote J; van Poppel H; de la Rosette J; Villers A; Malmberg A; Neijber A; Montorsi F
    Eur Urol; 2014 Oct; 66(4):655-63. PubMed ID: 24954791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.
    Kumar S; Shelley M; Harrison C; Coles B; Wilt TJ; Mason MD
    Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD006019. PubMed ID: 17054269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent complete androgen blockade in metastatic prostate cancer.
    Rambeaud JJ
    Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent androgen suppression in patients with prostate cancer.
    De La Taille A; Zerbib M; Conquy S; Amsellem-Ouazana D; Thiounn N; Flam TA; Debré B
    BJU Int; 2003 Jan; 91(1):18-22. PubMed ID: 12614243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.